Objective The aim of this study was to determine the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in estimating tumor aggressiveness in patients with clinical stage I endometrial cancer and the correlation between aggressiveness and expression of glucose transporter 1 (GLUT-1).
Methods 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed on 43 patients with clinical stage I endometrioid endometrial cancer. 18F-fluorodeoxyglucose uptake was quantified by calculating the maximum standardized uptake value (SUVmax) and GLUT-1 expression status based on immunohistochemistry.
Results The mean (SD) SUVmax of the primary tumor was 8.55 (5.04). The mean SUVmax and GLUT-1 expression in stage IB and stage IC were significantly higher than that in stage IA (P = 0.001; P = 0.003). The mean (SD) SUVmax was 6.81 (4.55) in grade 1, 10.92 (4.61) in grade 2, and 15.35 (1.34) in grade 3 (grade 1 vs grade 2 and 3; P = 0.005). The mean (SD) GLUT-1 expression was 1.17 (0.94) in grade 1, 2.00 (0.94) in grade 2, and 3.00 (0.00) in grade 3 (grade 1 vs grade 2 and 3; P = 0.017).
Conclusions Tumor aggressiveness, such as myometrial invasion or tumor grade, had a positive correlation with the SUVmax and GLUT-1 expression in patients with clinical stage I endometrioid endometrial cancer.
- Endometrial cancer
- 18F-FDG PET/CT
- Tumor aggressiveness
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Dong Wook Lee and Gun Oh Chong equally contributed to this work as co-first authors.